Research & Development Focus

With a strong focus on R & D, we have 8 high precision, integrated and scaled manufacturing facilities with global certifications and approvals like US FDA, C.E and ISO. Since fiscal year 2018, we have sold 30 new products including a patented portfolio of arthroscopy products.

We have 35 patents in U.S, Europe and India with 29 patent applications pending as on 31st March 2021. We also have 23 stock keeping units unique to Healthium.

Our manufacturing facilities employ technology that we have largely developed in-house to ensure high quality and to allow for extensive customization of our products to meet our customers’ diverse needs.

Driving Innovation

  • First barbed sutures in India with a triangular stopper which helps in faster wound closure.
  • Ligating clips with an innovative, patent-pending design which provides a secure grip in surgeries.
  • Patented sutures which are used in surgical interventions during post-partum haemorrhage, a leading cause of maternal mortality in India.
  • Anti-microbial gloves Trushield for which we are the sole Indian manufacturer.
  • Our arthroscopy range has several patented products for shoulder and knee interventions.
  • We were the first medical technology company in India to use a laser drilling process in needle manufacturing, which enables us to produce smaller needles with precise dimensions and consistent quality.


(formerly known as Healthium Medtech Private Limited)

472/D, 13th Cross, 4th Phase, Peenya Industrial Area, Peenya Industrial Area Phase IV, Peenya, Bengaluru, Karnataka - 560 058, INDIA

CIN: U03311KA1992PLC013831

For any queries or complaints write to

Customer care number


“Healthium Medtech Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its equity shares and has filed a draft red herring prospectus (“DRHP”) with the Securities and Exchange Board of India. The DRHP is available on the website of the SEBI at as well as on the websites of the book running lead managers, ICICI Securities Limited, CLSA India Private Limited, Credit Suisse Securities (India) Private Limited and Nomura Financial Advisory and Securities (India) Private Limited, at,, and, respectively, and the websites of the stock exchange(s) at and, respectively. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" of the RHP / Prospectus, when available. Potential investors should not rely on the DRHP for any investment decision.”

We use cookies to ensure you get the best experience on our website. Click here to view cookie policy